Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Benzonatate
Drug ID BADD_D00240
Description Benzonatate is an oral antitussive drug used in the relief and suppression of cough in patients older than ten years of age.[A5790] Currently, benzonatate is the only non-narcotic antitussive available as a prescription drug.[A189519] It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs and pleura involved in the cough reflex. Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.[A5790] Because its chemical structure resembles that of the anesthetic agents in the para-amino-benzoic acid class (such as [procaine] and [tetracaine]), benzonatate exhibits anesthetic or numbing action.[L11193] Although it not prone to drug misuse or abuse, benzonatate is associated with a risk for severe toxicity and overdose, especially in children.[A189513]
Indications and Usage Benzonatate is indicated for the symptomatic relief of cough.[L11193]
Marketing Status approved
ATC Code R05DB01
DrugBank ID DB00868
KEGG ID D00242
MeSH ID C029755
PubChem ID 7699
TTD Drug ID D0Q2ES
NDC Product Code 72789-014; 72789-232; 82982-023; 10888-8126; 51655-754; 55154-3372; 61919-573; 61919-638; 63187-928; 64380-713; 67296-1549; 67296-1768; 68382-091; 68788-8133; 71335-1329; 71335-1553; 72789-230; 72789-231; 72865-118; 11788-027; 11788-028; 42806-715; 53002-0413; 53002-5891; 63629-2474; 65162-536; 70934-884; 70934-893; 71205-037; 71205-887; 71335-1544; 72789-025; 17381-295; 0904-7153; 11788-029; 51655-776; 53002-0412; 55154-7995; 55700-923; 62332-427; 63629-2444; 65162-537; 67296-1454; 70934-675; 61919-517; 62135-440; 63187-606; 63187-799; 63629-1229; 65841-614; 68084-214; 71205-067; 71205-643; 71205-971; 82982-064; 10888-8125; 65655-0010; 31722-957; 42708-171; 50090-4969; 50090-6080; 50090-6205; 55700-922; 63187-076; 63739-029; 67296-1475; 68071-2624; 68788-7560; 68788-8405; 69452-144; 71205-659; 71205-662; 71205-885; 43063-979; 50090-6387; 51224-001; 53002-0411; 60429-914; 62332-426; 63187-185; 63629-2443; 63629-2473; 67296-1833; 68071-2562; 68788-7607; 70518-2491; 71205-605; 72189-192; 31722-956; 42806-714; 50090-5409; 50090-6294; 53002-5890; 59762-1122; 62135-441; 63629-2475; 63629-2476; 68071-5223; 68788-8127; 70518-2873; 70518-3542; 71205-699; 71335-1927; 71335-2021; 72865-117; 0904-6564; 42192-618; 43063-980; 51224-010; 61919-400; 63187-016; 67296-1751; 69452-143; 71205-886; 71335-0725; 71335-1880; 72865-119; 66499-0068; 81066-0003; 31722-958; 50090-3228; 50090-6228; 51655-762; 65841-843; 67296-1450; 67296-1576; 71205-853; 71335-0031; 71335-0688; 71335-1968; 71610-692; 72189-194; 82982-031; 50090-5986; 53002-5892; 60429-927; 60760-700; 63629-9189; 64380-712; 67296-1290; 67296-1464; 67296-1782; 68071-5083; 68382-247; 68788-7569; 68788-8329; 68788-8336; 71205-632; 71205-673; 71205-972; 0615-8403; 11014-0044; 22568-1005; 65655-0011; 42192-617; 42708-082
UNII 5P4DHS6ENR
Synonyms benzonatate | Tessalon
Chemical Information
Molecular Formula C30H53NO11
CAS Registry Number 104-31-4
SMILES CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Acidosis14.01.03.0020.000031%
Agitation17.02.05.012; 19.06.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000031%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000031%Not Available
Anxiety19.06.02.0020.000031%
Apnoea22.02.01.0010.000063%
Arrhythmia02.03.02.0010.000094%Not Available
Bradycardia02.03.02.0020.000047%Not Available
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.0010.000594%
Chills15.05.03.016; 08.01.09.001--
Circulatory collapse24.06.02.001--Not Available
Coagulopathy01.01.02.0010.000031%Not Available
Coma17.02.09.0010.000031%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.000188%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cyanosis24.03.01.007; 22.02.02.007; 23.06.04.005; 02.11.04.0040.000031%
Depressed level of consciousness17.02.04.0020.000047%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000100%
Drug hypersensitivity10.01.01.0010.000903%Not Available
Dry skin23.03.03.0010.000031%
Dysphagia07.01.06.0030.000069%
Dyspnoea02.11.05.003; 22.02.01.0040.000100%
Eye irritation06.04.05.003--Not Available
Feeling abnormal08.01.09.014--Not Available
Hallucination, visual19.10.04.007--Not Available
Headache17.14.01.001--
Hypersensitivity10.01.03.0030.000047%
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene